Gene therapy recipients monitored for hidden risks
NCT ID NCT02390297
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 26 times
Summary
This study follows 11 people who previously received an experimental HIV gene therapy called Cal-1. The main goal is to watch for any delayed side effects from the treatment. Researchers will also check how long the modified cells survive in the body. No new treatment is given; this is a long-term safety observation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV -1 INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Quest Clinical Research
San Francisco, California, 94115, United States
-
UCLA CARE Center
Los Angeles, California, 90035, United States
Conditions
Explore the condition pages connected to this study.